Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2019

View Archived Issues

GP-205 shows promising preclinical profile supporting further development as HCV infection therapy

Activation-induced cytidine deaminase mediates T790M resistance mutation to TKI-treated lung cancer

E7 oncogene expression sensitizes to an Aurora kinase inhibitor in HPV+ head and neck cancer

Microenvironment-on-a-chip brings new insights into Herceptin

Analogues K2A and R13A of mutacin 1140 demonstrate efficacy in animal models of MRSA infection

Medshine Discovery divulges new angiotensin AT2 receptor antagonists

Bristol-Myers Squibb patents formylpeptide FPR1 and FPR2 receptor agonists

Synthon Biopharmaceuticals patents anti-SHPS-1 antibodies

Bayer and DKFZ present MAP4K1 inhibitors

Checkpoint protein promotes NASH, may represent new therapeutic target

Sesen Bio presents positive preliminary data from registration phase III VISTA study

Pivotal trial of inebilizumab achieves primary and key secondary endpoints

Discovery and characterization of novel CID peptidomimetic, DB-550

First cohort dosed in phase I study of PLN-74809

Merus and Betta Pharmaceuticals enter agreement to develop MCLA-129 in China

Urovant initiates phase IIa study of vibegron for IBS-related abdominal pain

NanoFlu elicits promising immune responses in phase II trial

Jounce completes first cohort enrollment in phase I study of JTX-4014 in solid tumors

Five new Japanese approvals for Keytruda

Horizon Pharma and HemoShear Therapeutics to jointly discover therapeutics for gout

Knopp Biosciences Baylor College of Medicine to develop treatments for KCNQ2 neonatal encephalopathy

Mutations in ROBO4 gene tied to bicuspid aortic valve and thoracic aortic aneurysm

Evelo begins phase I/II trial of EDP-1503 in combination with Keytruda

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...